SLAMF7 (or CS1) is expressed on a variety of lymphocytes, including subsets of B and T cells, natural killer cells and plasma cells. SLAMF7 is the target of the mono clonal antibody elotuzumab. The development of CAR T cells directed against SLAMF7 may be more challenging because of this antigen’s expression on T-cell subsets which may lead to fratricide.¹

CD38 is expressed on plasma cells and is the target of monoclonal antibodies such as daratumumab and isatuximab. It is also expressed on several other lymphoid and myeloid cells, including hematopoietic precursors, raising concerns about on-target, off-tumor toxicity. The levels of expression of CD38 may also decline during the course of the disease or under the selective pressure of CD38- targeted treatment. This problem may be overcome by agents inducing selective upregulation of CD38, such as all-trans retinoic acid, histone deacetylase inhibitors or ruxolitinib.^2-4

BCMA is preferentially expressed on mature B cells including plasma cells. It is important for B-cell development and critical for proliferation and survival. BCMA is a cell surface receptor of the tumor necrosis factor receptor superfamily and binds to B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL). BCMA expression can vary due to cleavage by γ-secretase leading to shedding from the cell surface.

TACI is another member of the tumor necrosis factor receptor superfamily expressed on B-cell subsets and plasma cells.

CD19 is widely expressed on B cells but considerably less on plasma cells. It has been postulated that it may be expressed on “myeloma stem cells”. Recent analysis by super-resolution microscopy revealed a broader low-level expression on a fraction of myeloma cells (10-80%).⁵

GPRC5D is an orphan receptor ubiquitously expressed on healthy and malignant plasma cells but not on normal tissues except the immune-privileged tissue of hair follicles. High GPRC5D expression on MM cells was associated with adverse prognosis in the CoMMpass dataset.⁶

FcRH5, also known as FcRL5, IRTA2, and CD307, is a 120 kDa protein with sequence homology to classical Fc receptors. The type 1 transmembrane FcRL family proteins contain from three to nine immunoglobulin-like domains. They are differentially expressed within the Bcell lineage and can either promote or inhibit B-cell proliferation and activation. FcRH5 is expressed on MM cells and plasma cells and, to a lesser extent, on normal B cells.⁷

By far the most clinically advanced ADC is belantamab mafodotin, a humanized IgG1 anti-BCMA monoclonal antibody that is conjugated, via a non-cleavable linker, to the microtubule inhibitor, monomethyl auristatin F (MMAF). MMAF blocks the myeloma cell cycle at the G2/M phase leading to apoptosis. Afucosylation of the ADC Fc portion enhances the affinity to Fc receptors of innate immune cells, which increases immune-mediated recognition and elimination. Therefore, belantamab mafodotin can also be considered as immunotherapy.¹⁰ (Figure 1)

Two dose levels (2.5 mg/kg or 3.4 mg/kg, intravenously every 3 weeks) of belantamab mafodotin were tested in the pivotal randomized phase II DREAMM-2 study in heavily pretreated (6-7 prior lines of therapy) patients with relapsed and/or refractory MM (RRMM): The efficacy of the ADC was comparable at the two dose levels, with the overall response rate (ORR) being 31% versus 35% and the progression-free survival (PFS) being 2.8 months versus 3.9 months in the 2.5 mg/kg and 3.4 mg/kg cohorts, respectively. Duration of response was 11.0 and 6.2 months, while the overall survival was 14.9 and 14.0 months, respectively (Table 1).¹¹

The MMAF component of belantamab mafodotin is responsible for clinically significant ocular toxicity: microcyst- like epithelial changes of the cornea.¹² Clinically, patients experience blurred vision, decreased visual acuity and dry eyes. In DREAMM-2, keratopathy was noted in 70-75% of patients and was grade ≥3 in 27% (with the 2.5 mg/kg dose) and 21% (with the 3.4 mg/kg dose) of the patients. Keratopathy was the most common adverse event leading to dose reductions and delays as well as to permanent treatment discontinuation. It is therefore mandatory to schedule regular ophthalmological examinations when treating MM patients with this novel ADC.

In summary, the DREAMM-2 study demonstrated that belantamab mafodotin has clinically significant efficacy as a single agent and it was approved (at a dose of 2.5 mg/kg every 3 weeks) in both the USA and in Europe in 2020 for the treatment of RRMM patients after four lines of therapy (including a proteasome inhibitor, immunomodulatory drug and an anti-CD38 monoclonal antibody).

Based on the DREAMM-2 study results, belantamab mafodotin is currently being assessed in trials at earlier lines of treatment and with different combination partners: ⁹ immuno-oncological antibodies (DREAMM-4,¹³ DREAMM-5) or established MM therapeutics lenalidomide + dexamethasone (DREAMM-6),¹⁴ pomalidomide + dexamethasone,¹⁵ bortezomib + dexamethasone (DREAMM-6,¹⁴ DREAMM-7) and bortezomib + lenalidomide + dexamethasone (DREAMM-9).

Table 1 summarizes key studies of this program for which efficacy and toxicity data are already available. Further details and summaries of all ongoing studies with belantamab mafodotin are provided in comprehensive recent reviews.^8,9,16

MEDI2228 is another ADC targeting BCMA. The cytotoxic moiety is tesirine, a DNA crosslinking pyrrolobenzodiazepine dimer attached to the antibody via a protease- cleavable linker. This toxin induces DNA crosslinking and the DNA damage response.¹⁷ The ADC was designed to specifically target the membrane-bound BCMA protein, so that its activity is not affected by the levels of soluble BCMA.

The results of the phase I, first-in-human, dose escalation and expansion study (NCT03489525) involving 82 heavily pretreated RRMM patients were presented at the 2020 ASH annual meeting.¹⁸ The maximum tolerated dose was found to be 0.14 mg/kg every 3 weeks and, within the cohort given this dose (41 patients), the ORR was 61% (24% with a very good partial response and 37% with a partial response). This efficacy was similar to that observed in the belantamab mafodotin DREAMM-1 trial (Table 1).¹⁹

However, unexpected ocular toxicity occurred: 54% of the patients given the maximum tolerated dose developed an as-yet unexplained photophobia. This toxicity, which led to treatment discontinuation in a large subgroup of patients, appears to be unrelated to the belantamab mafodotin-induced keratopathy. Other MEDI2228-induced toxicities were thrombocytopenia (32%), rash (29%) and pleural effusions (20%).¹⁸

The ADC AMG 224 is a BCMA-directed IgG1 monoclonal antibody coupled to the tubulin inhibitor mertansine (also called DM1). The results of the first phase I dose expansion and escalation study (NCT02561962) have recently been reported.²⁰ In all 40 patients, the ORR was 23%, including two patients with a stringent complete response and two with a very good partial response. The ADC was tolerated up to the defined maximum tolerated dose of 190 mg intravenously every 3 weeks. Hematologic toxicity, mainly thrombocytopenia (40% ≥*********grade 3), was the most common adverse event. No dose reductions, delays or ADC discontinuation were necessary due to ophthalmological adverse events (any grade: 30%). Ocular toxicity seems to be less common with this ADC than with the MMAF-conjugated belantamab mafodotin (Table 1).²⁰

The following ADC are in (pre-)clinical development, but no relevant clinical efficacy data have been reported so far.

The ADC CC99712, which is currently being evaluated in a phase I study (NCT04036461), also targets BCMA. Its toxic payload is the tubulin inhibitor monomethyl auristatin E.⁹

TAK-169 and TAK-573 are two CD38-directed ADC in early clinical development. TAK-169 is linked to a deimmunized Shiga-like toxin A subunit. Preclinical studies demonstrated highly effective lysis of primary MM cells in vitro.²¹ No clinical data regarding the ongoing phase I study (NCT04017130) are yet available. TAK-573 targets a CD38 epitope for which cross-reactivity with the currently approved anti-CD38 monoclonal antibodies, daratumumab and isatuximab, is not anticipated. It is linked to two attenuated interferon α2b molecules. A first-inhuman, dose-escalation, phase I trial (NCT 3215030), which is also assessing different treatment schedules, is currently recruiting patients. Early data focused on pharmacokinetic and immunological parameters have revealed limited clinical responses in MM patients across all four treatment cohorts.²²

The MMAF-coupled ADC FOR-46, currently undergoing evaluation in a phase I, dose-escalation study (NCT03650491), is directed against the complement regulatory protein CD46. This ADC targets a tumor-specific epitope of CD46 and efficiently induces macropinocytosis. ²³

The cytotoxic potential of the ADC HDP-101 is based on a synthetic version of the Amanita phalloides toxin amanitin, a specific inhibitor of RNA polymerase II.²⁴ This inhibition of gene transcription and protein synthesis is cell cycleindependent, an important property given that in many cases a large fraction of MM cells are not proliferating. This rare property may be a clinically important characteristic of HDP-101. Due to its chromosomal location, RNA polymerase II is frequently co-deleted with TP53 in del(17p). MM cells with this high-risk feature are therefore likely to be highly sensitive to HDP-101. Promising preclinical safety and activity data have been reported²⁵ and a first-inhuman, phase I, dose escalation and expansion study for RRMM patients is planned for 2021.²⁶

Proof-of-principle of the validity of this strategy was recently provided by a study on AMG 420, a bispecific Tcell- engager (BiTE^®) targeting BCMA.²⁷ In a dose-escalating phase I study in RRMM,²⁷ the ORR was 70% at a dose of 400 mg/day and some patients responded for more than 1 year. In a single-center study, the median PFS was 23.5 months for responders (n=10).²⁸ Like the CD19xCD3 BiTE^® blinatumomab, AMG 420 has a short half-life with rapid elimination from the circulation. Continuous infusion over weeks was therefore necessary, causing substantial inconvenience to patients. In light of the multiple other TCE variants with longer half-lives under clinical investigation, the manufacturer did not pursue further development of AMG 420. Numerous abstracts on TCE were presented at the ASH annual meeting in 2020, and initial clinical data on at least seven new TCE were reported (Table 2).

Teclistamab (JNJ-64007957) is a humanized bispecific IgG4 antibody that binds to BCMA on target cells and CD3 on T cells (BCMA x CD3). Currently being evaluated in an ongoing phase I study, teclistamab is available in both intravenous and subcutaneous formulations, and is administered on a weekly schedule. Updated results from 149 patients, presented at ASH in 2020, showed a favorable safety profile and promising efficacy.²⁹ Although cytokine release syndrome (CRS) was seen in more than half of the patients (55% in the intravenous group, and 64% in the subcutaneous group), no grade 3 CRS was recorded, and no dose-limiting toxicity was reported at the recommended phase II dose of 1500 mg/kg subcutaneously. The ORR was 73%, with 55% of the patients achieving a very good partial response or better at the recommended phase II dose, including patients with triple-class and penta-drug RRMM. However, follow-up is limited (median 3.9 months) and it remains to be seen if these responses are durable and if patients with highly proliferative disease or extramedullary involvement have a similar benefit. A phase II study has been initiated.

Another TCE that binds BCMA and CD3, REGN5458, was evaluated in 45 patients in a dose-escalation, phase I study.³⁰ This TCE was administered intravenously on a weekly schedule followed by a maintenance phase in which it was administered every 2 weeks. CRS occurred in 38% of patients, but there were no episodes of grade ≥3 CRS. The ORR increased in a dose-dependent manner and was 62.5% (5/8 patients) at the highest dose level used. Responses were deep and 95% of responders achieved a very good partial response or better. The median duration of follow-up was 2.6 months. The phase II part of the study is currently enrolling patients.

TNB383B is a BCMA x CD3 fully human IgG4 antibody with improved binding to cell surface BCMA and a half-life of 2-3 weeks.³¹ It is administered once every 3 weeks and is given intravenously. Decreased affinity to CD3 may be responsible for the lower rate of CRS associated with this product. The all-grade CRS rate was 45% in the phase I dose escalation study which enrolled 58 patients.³² The ORR was 80% in the highest dose group (n=15). Two patients died from COVID-19 infection.

AMG 701 is a derivative of AMG 420 with a modified BiTE^® structure resulting in an extended half-life of around 112 hours, making it suitable for once weekly dosing. A total of 82 patients were treated in the doseescalation phase I study. The ORR was 26% and 83% in the entire study population and in the most recent evaluable cohort, respectively.³³ Extramedullary disease was excluded in subcohorts of this study. AMG 701 was given intravenously on a weekly schedule with a step-up dose during the first cycle to reduce CRS, which was seen in 61% of patients including 7% who experienced grade 3 CRS. Exposure to free drug was affected to some extent by the levels of soluble BCMA, suggesting a possible interaction between the TCE and soluble antigens. The recommended phase II dose has yet to be determined.

PF-06863135 is a BCMA x CD3 humanized IgG2a antibody being evaluated in a subcutaneous formulation in an ongoing phase I study. At the 2020 ASH meeting, results from the first 18 patients were presented, indicating an ORR of 33% in the overall population, and 75% in patients receiving the two highest dose levels. The CRS rate was 61% with no CRS grade 3 events.³⁴

This asymmetric, two-arm, humanized IgG BCMA x CD3 antibody is also being evaluated in a phase I study.³⁵ The initial data from 19 patients, presented at the ASH meeting in 2019, indicated an ORR of around 80% at effective dose levels, but also CRS in over 80% of patients including one case that was fatal.³⁶ The recommended phase II dose has yet to be determined and follow-up data are awaited.

The specific and consistent expression of BCMA on plasma cells makes this antigen an ideal target protein for T-cell-based immunotherapy. However, a number of other cell surface receptors share these characteristics and are being targeted with TCE in ongoing trials. This is of particular interest, as BCMA downregulation³⁷ and even irreversible loss³⁸ of BCMA expression has been reported following treatment with targeted immunotherapies.

Talquetamab is a GPRC5D x CD3 TCE which has been evaluated in a dose-escalation phase I study,³⁹ in which it was administered both intravenously and subcutaneously. A total of 175 patients were treated and a dose of 405 μg/kg was defined as the recommended phase II dose. At this dose, 69% (9/13) of patients responded, including two who had stringent complete responses. Dose-limiting toxicities included increased lipase (grade 4) and maculopapular rash (grade 3) in one and two subjects, respectively. Skin-related off-target effects and nail disorders were seen in a significant proportion of patients. CRS occurred in 55% of the patients but was generally low grade with no grade ≥3 CRS in those administered the product subcutaneously.

This FcRH5 x CD3 humanized IgG-based TCE is being evaluated in an ongoing phase I, dose escalation and expansion trial (NCT03275103). FcRH5 is expressed on MM cells and plasma cells and, to a lesser extent, on normal B cells.⁷ The ORR was 53% (18/34) in patients receiving active doses, and six patients achieved minimal residual disease negativity at a threshold of 10⁵. CRS occurred in 76% of patients with one patient experiencing grade 3 CRS.⁴⁰ The dose escalation and expansion phase is ongoing.

In summary, there is an extensive pipeline of TCE targeting BCMA and other antigens, with response rates to these products being between 50% and 80%, including some deep responses in heavily pretreated patients. CRS is common during the first cycle of treatment, but is manageable with step-up dosing schedules and the use of prophylaxis. Short intravenous infusions or subcutaneous formulations offer convenient administration in the outpatient setting. Several other TCE are in early clinical development with clinical data yet to be reported.

More advanced data have been reported on idecabtagene vicleucel (ide-cel, bb2121) and ciltacabtagene autoleucel. In the phase I study of ide-cel, a BCMA-CD28 construct, 62 RRMM patients were treated with escalating doses from 50 to 800x10⁶ cells. The ORR was 76% with a 39% complete response rate and a median PFS of 8.8 months with a follow-up of 18.1 months. Toxicity was comparatively low with grade 3/4 CRS occurring in 7% and ICANS in 2% of patients.^46,47

In the phase II KarMMa trial of ide-cel, 128 RRMM patients were treated. The ORR was 73% with a complete response rate of 33% and a median PFS of 8.8 months. The rate of grade 3/4 CRS was 5% and that of ICANS was 3%.^48,49 In the ongoing KarMMa-2 study idecel is being evaluated in patients who have relapsed early following first-line therapy and in patients who achieved less than a very good partial response after autologous stem cell transplantation. The phase III study, KarMMa-3, is comparing ide-cel with standard-of-care regimens in RRMM.

Ciltacabtagene autoleucel (cilta-cel, LCAR-B38M or JNJ-4528), a BCMA-4-1BB construct with two BCMA binding domains, was first developed in China. The phase I trial, LEGEND-2, enrolled 57 patients. The ORR was 88% with 74% of patients achieving a complete response. The median PFS was 19.9 months. With regard to adverse events, the rate of grade 3/4 CRS was 7% and no grade 3/4 episodes of ICANS occurred.^50-52 Cilta-cel was then evaluated in the phase I/II CARTITUDE-1 trial with 97 patients treated so far. The ORR was 97% and the complete response rate was 67%. At a follow-up of 12.4 months the median PFS had not been reached and the 12 months PFS rate was 76.6%. The rate of grade 3/4 CRS was 5% while that of grade 3/4 ICANS was only 2%; however, there were also other delayed episodes of neurotoxicity reported in 9% of the patients in the latest follow-up.^53-55

In the ongoing CARTITUDE-2 study, cilta-cel is being evaluated following first-line therapy in patients who have not achieved a complete response after autologous stem cell transplantation or in those with prior exposure to a BCMA-targeting drug. Cilta-cel is also being evaluated in the phase III CARTITUDE-4 study comparing CAR T cells versus pomalidomide-based triplets in lenalidomide- refractory patients.

The disadvantages of currently available autologous CAR T-cell therapy include the long time needed for production and the reduced fitness of T cells due to the heavy pretreatment of the patients in current clinical trials. This may be overcome in part by preemptive T-cell collection early during the course of the disease. Off-theshelf allogeneic CAR T cells may be an alternative. Mailankody et al. presented preliminary data on the first allogeneic BCMA CAR T-cell study for RRMM at the ASH meeting in 2020. In these allogeneic CAR T cells the T-cell receptor is knocked out to avoid graft-versus-host disease and CD52 is knocked out to permit the use of an anti-CD52 antibody for selective and prolonged lymphodepletion to improve engraftment. Gene editing is performed with transcription activator-like effector nuclease (TALEN) technology. The ORR in the group given a dose of 320x10⁶ cells was 60% (6/9 patients) with no grade 3/4 CRS or ICANS or graft-versus-host disease.⁵⁶ CAR-transduced natural killer cord blood cells may be another potential source of future off-the-shelf cellular products.⁵⁷

Given the many therapeutic agents that are being developed within each immunotherapeutic class - ADC, TCE, and CAR T cells-much work will be required to assess their relative merits. Most data are available for ADC, for which a range of ocular toxicities have been observed, especially those affecting visual acuity. While belantamab mafodotin induces a clinically significant, reversible keratopathy in about a third of patients, other ADC are associated with lower rates of keratopathy (AMG224) or as yet unexplained photophobia (MEDI2228). However, as the latter two ADC have only been given to limited numbers of patients so far, it is too early to assess potential differences in side effects or even in efficacy.

The same considerations apply to TCE, despite their seemingly similar side-effect profiles, mainly CRS and cytopenias. However, based on early phase clinical trial data, some agents seem to cause CRS less frequently, e.g., TNB-3838, whereas others cause CRS in the majority of patients, yet mostly of minor grade. CC-93269 and talquetamab seem to induce grade 3/4 CRS in some patients. While TNB-3838 was specifically designed to induce less CRS by having a lower affinity for CD3, the reason for the higher CRS rates with other agents remains to be better understood. Of note, the route of administration appears to have an impact on side effects in general and on the rate of CRS specifically, as the rates of both were lower when teclistamab and talquetamab were given subcutaneously rather than intravenously. Interestingly, so far, the specific target of individual TCE does not appear to affect the side-effect profile. Again, it remains to be seen whether these distinctions between different agents of the same class will be confirmed in larger trials. However, most patients will favor subcutaneous administration, especially if lower rates of side effects will allow for outpatient use.

Regarding CAR T-cell approaches, the only available data relate to constructs that target BCMA. While phase III results are awaited, the numbers of patients in reported trials are higher and clinical development is more advanced when compared to those for TCE.

For the two most advanced constructs, ide-cel and ciltacel, grade 3/4 CRS and ICANS are relatively uncommon and less of a concern when compared to the side effects of CD19-directed CAR T-cell therapies. Nonetheless, there seem to be differences in the timing of onset of these toxicities. Ide-cel-associated CRS and ICANS emerge within the first 10 and 30 days, respectively, whereas the median times to onset of CRS and ICANS following cilta-cel treatment are 7 and 8 days after infusion, respectively. Moreover, delayed neurotoxicities associated with cilta-cel treatment, not attributable to ICANS, have been reported to occur even several months after infusion. This has implications for the logistics and timing of the required observation period after CAR Tcell therapy.

As it is highly unlikely that we will ever have randomized trials comparing different members of the same class of agents, we will have to wait for larger clinical trials and ultimately real-world post-approval data to tease out the specific characteristics of individual members of the immunotherapeutic armamentarium.

Despite the unprecedented responses to both CAR T cells and TCE, all patients eventually seem to relapse. It is therefore very important to understand mechanisms of resistance to the different immunological therapies,⁵⁸ including lack of CAR T-cell persistence in MM patients, MM cell target antigen loss,³⁸ and functional inactivation of T cells by an immunosuppressive microenvironment.⁵⁹ Based on translational data, promising strategies to improve the duration of response to MM immunotherapy include: (i) generation of CAR T cells with a higher potential for persistence in vivo (e.g., by in vitro generation of less exhausted effector-type and more functionally fit naive cells);^60,61 (ii) targeting more than one MM tumor antigen simultaneously by dual CAR T-cell approaches; ^60,61 and (iii) concurrently inhibiting endogenous tumor escape mechanisms, such as T-cell-expressed immune checkpoint molecules or myeloid cell arginase-mediated arginine deprivation.⁵⁹

With increasing treatment options, there needs to be a focus on the timing and sequencing of compounds and strategies. For the time being and likely for the next few years, this issue will be answered (or dictated) by which of these different immunotherapies have been approved for clinical use. However, there is strong interest in using these agents at earlier lines of treatment with less exhausted T cells present in the bone marrow to be exploited by TCE or available to be transduced into CAR T cells. In this regard, results from CAR T-cell trials involving less heavily pretreated patients, although still RRMM patients, do not appear to show greater efficacy, notwithstanding all the limitations of inter-trial comparisons and small numbers of patients.

Another important aspect relates to how to use cellular or antibody-based immunotherapy best in hard-to-treat populations of patients, such as those with high-risk MM, early clinical relapse, or extramedullary disease. While reported TCE trials have been too small to allow any conclusion to be drawn, for ide-cel an initial subgroup analysis found that high-risk markers, such as a revised International Staging System score of 3, even in late-stage refractory disease, are still associated with lower response rates and a shorter median PFS.⁴⁹ For the time being, cellular therapies will be an attractive option for otherwise hard-to-treat, high-risk patients. However, it is possible that cellular immunotherapy might be best used in good-risk patients to induce deep and durable, sustained minimal residual disease negativity in an attempt to cure the disease rather than chasing high-risk disease that is inherently biologically capable of adapting quickly to and thereby prevailing the attack of modified T cells. Preliminary indications can be expected from ongoing studies that address the efficacy of CAR T-cell therapy in patients with early relapse or insufficient response after first-line therapy (e.g., KarMMa-2, CARTITUDE-2) as well as from subgroup analyses of the phase III trials KarMMa-3 and CARTITUDE-4 in relapsed patients after two to four and one to three lines of therapy, respectively.

Other questions regarding the best use of cellular or antibody-based immunotherapies include their place relative to autologous stem cell transplantation, their role in post-transplant consolidation, in the treatment of persistent minimal residual disease positivity, and their potential to replace or shorten maintenance therapy. One fundamental difference between these two immune-based approaches is how quickly they can be provided to a given patient. CAR T cells need to be manufactured, requiring several weeks of planning, scheduling, and possibly bridging treatment, at least with current technology and constructs. This setting appears to be best integrated into an established treatment algorithm, similar to that for autologous stem cell transplantation, or in a setting of consolidation or minimal residual disease. TCE, conversely, are readily available and represent an outpatient community- based option, although uncertainties relating to repeated dosing and treatment-free intervals need to be explored. However, TCE are suitable candidates for integration into combination regimens, a strategy that has previously been proven to result in superior outcomes for patients.

Last but not least, the most frequently asked question relates to patient selection. As the first ADC was approved in Europe and the USA in 2020, and as the first CAR T-cell construct is expected to be approved early in 2021, this is a clinically pressing concern (Figure 2).

Cellular immunotherapy should not be limited to certain age groups, but should rather be considered for use in fit patients, without significant comorbidities, who would tolerate intensive care treatment if CRS or ICANS occurs. Patients would need to be able to travel to the designated cell-therapy centers and close collaboration between these centers and community-based hematologists is required.

T-cell engagers, such as TCE or modified BiTE^®, are associated with a lower risk of immune-mediated toxicities such as high-grade CRS or ICANS, as a result of which less-fit patients can be considered as treatment candidates. In addition, patients with high disease dynamics requiring urgent treatment might benefit from the immediate availability of TCE.

Finally, ADC may be potentially suitable for frail patients if the patients are closely monitored for keratopathy or other ophthalmological side effects. However, these toxicities may impact and limit activities of daily life. The relatively long intervals of 3 weeks between therapy administration may more easily allow for treatment of patients with limited mobility. (Figure 2)

Despite all remaining open questions and issues that still need to be addressed, and hopefully answered and resolved within the next years, we are now, without any doubt, at the dawn of a new era that will significantly improve patients’ outcome. There is a light at the horizon towards curing MM.